Search
Propacetamol
go.drugbank.com/drugs/DB09288Investigational[A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. … [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSClenoliximab
go.drugbank.com/drugs/DB06241ExperimentalClenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalIt is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.
Demecarium
go.drugbank.com/drugs/DB00944ApprovedDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.
Synonyms: Demecarium ionRiluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. … Riluzole is marketed as Rilutek by Sanofi.
Categories: Compounds used in a research, industrial, or household settingProducts: RILUTEK® TABLETAS X 50MGBetaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Categories: Antihypertensive Agents Indicated for HypertensionMK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. … It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
AVI-4557
go.drugbank.com/drugs/DB05447ExperimentalAVI-4557 is therefore indicated to limit toxicity for patients receiving highly-toxic therapeutic drugs for treatment of anxiety, cancer, and a number of other serious conditions. … in clearance and an increase in maximal blood concentration (Cmax).
R411
go.drugbank.com/drugs/DB05468ExperimentalR411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. … It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.